IDEXX Laboratories, Inc. (IDXX)
| Market Cap | 45.11B |
| Revenue (ttm) | 2.86B |
| Net Income (ttm) | 674.21M |
| Shares Out | 85.53M |
| EPS (ttm) | 7.77 |
| PE Ratio | 68.61 |
| Forward PE | 70.92 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 6 |
| Last Price | $533.18 |
| Previous Close | $529.92 |
| Change ($) | 3.26 |
| Change (%) | 0.62% |
| Day's Open | 524.31 |
| Day's Range | 522.58 - 535.08 |
| Day's Volume | 433,042 |
| 52-Week Range | 280.53 - 573.99 |
IDEXX (IDXX) registers strong contribution from its CAG business in the first quarter despite pandemic-induced challenges.
Idexx (IDXX) delivered earnings and revenue surprises of 36.63% and 5.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
WESTBROOK, Maine, May 4, 2021 /PRNewswire/ -- Achieves reported revenue growth of 24% and organic growth of 21%, driven by CAG Diagnostics recurring revenue growth of 27% as reported and 23% organic Del...
In the latest trading session, Idexx Laboratories (IDXX) closed at $548.99, marking a -0.66% move from the previous day.
Joining fellow medical sector stock Veeva on this list of top long-term growth stocks, Idexx has investors wagging their tails ahead of Q1 earnings. The post After 240% Run, Long-Term Leader Sniffs Out ...
IDEXX (IDXX) first-quarter top line is expected to have benefited from strength in CAG and LPD businesses.
This coming week may mark the last thrust up in this equity rally.
Market Rally, Leaders Suffer Further Damage: United Airlines, Freeport McMoran, Idexx Labs In Focus
Market rally suffers further damage, leaders hard hit: United Airlines, Freeport McMoran, Idexx Labs in focus. Investor's Business Daily has been helping people invest smarter results by providing exclu...
The potential is staggering.
WESTBROOK, Maine, April 8, 2021 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, has sched...
Overvalued stocks at record highs for major stock indices are too risky. These 5 stocks are too overvalued to own now.
Here's how you can profit off the booming $54 billion veterinary care industry.
These top-ranked stocks are likely to beat on the bottom lines in their next releases.
Idexx Laboratories (IDXX) closed at $487.66 in the latest trading session, marking a -0.76% move from the prior day.
IDEXX's (IDXX) Global Reference Lab revenues are growing organically in the United States and in international markets.
One of the best-performing investment funds of the last decade is not a secretive Wall Street hedge fund. It's not even a private office or exchange-traded fund.
In light of the Federal Reserve's announcement that it will pause interest rate hikes through 2023, investors may want to have a look at these four good companies that have strong Piotroski F-scores acc...
Investors in IDEXX stock are betting on continued growth in the company's core business and continued interest by investors in this segment. The post Idexx Laboratories Is a Great High-Margin Growth Pla...
Investors are optimistic about IDEXX (IDXX) backed by robust CAG and LPD revenues growth and strong global performance boosting the top line.
IDEXX Laboratories (IDXX) has been struggling lately, but the selling pressure may be coming to an end soon
The pandemic puppy boom is real, and so are sales for these three pet stocks.
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?
Is (IDXX) Outperforming Other Medical Stocks This Year?
The S&P 500 is up a solid 75% from the lows of March 2020 and many large-cap stocks are now trading near all-time highs. In our indicative theme of Stocks Poised For A Split, we've identified a group of...
Idexx Labs is an animal health company putting all four feet forward.
Idexx Labs is riding the growth trends in pet healthcare.
IDXX stock has soared over the past year, and is continuing its climb today thanks to the recommendation of one well-known analyst. The post IDXX Stock: Why Pet Care Play Idexx Laboratories Is Moving To...
WESTBROOK, Maine, Feb. 16, 2021 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, will part...
Pet stocks have performed very well recently, and many analysts believe that this trend will continue as the industry grows. The post 7 Pet Stocks for Animal Lovers and Investors Alike appeared first on...
IDEXX (IDXX) registeres strong contribution from its CAG business in the fourth quarter despite pandemic-induced challenges.
IDEXX Laboratories, Inc. (IDXX) CEO Jay Mazelsky on Q4 2020 Results - Earnings Call Transcript
Idexx (IDXX) delivered earnings and revenue surprises of 40.56% and 5.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of IDEXX Laboratories (NASDAQ:IDXX) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share were up 69.23% year over year to $1.76, which beat the estimate of $...
WESTBROOK, Maine, Feb. 2, 2021 /PRNewswire/ -- Achieves fourth quarter reported revenue growth of 19% and organic growth of 17%, driven by CAG Diagnostics recurring revenue reported growth of 23% and or...
On Tuesday, February 02, IDEXX Laboratories (NASDAQ:IDXX) will release its latest earnings report. Here is Benzinga's outlook for the company.
Advancing diversity in veterinary medicine through nine full scholarships and integrated support WESTBROOK, Maine, Jan. 28, 2021 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader ...
IDEXX's (IDXX) fourth-quarter top line is likely to have benefited from strength in CAG and LPD businesses.
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These three healthcare stocks all had a good year in 2020, and their businesses look to have plenty of growth again in 2021.
Biden's administration plans to address climate change and take ESG initiatives. This call for investing in Shopify (SHOP), Magna International (MGA), IDEXX Lab (IDXX), Facebook (FB) and PayPal (PYPL).
Rising pet ownership rates and a steadily increasing average household spending provide a powerful tailwind to this investment theme. Pet food, animal health, veterinary equipment, and specialized e-com...
Earnings growth is considered the most important variable in influencing the share price. Notably, some of the stocks that boast of superb earnings growth include D.R.
WESTBROOK, Maine, Jan. 11, 2021 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, has sched...
After already rising over 109% since getting a checkup with the Wall Street vet, animal health care leader Idexx has bitten into a new buy zone. The post Breakout Stocks To Watch In 2021: Idexx Stock Bi...
We have selected five MedTech growth stocks with further rooms for improvement in 2021.
About IDXX
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems a... [Read more...]
| Industry Diagnostics & Research | IPO Date Jun 21, 1991 |
| CEO Jonathan Jay Mazelsky | Employees 9,300 |
| Stock Exchange NASDAQ | Ticker Symbol IDXX |
Financial Performance
In 2020, IDXX's revenue was $2.71 billion, an increase of 12.45% compared to the previous year's $2.41 billion. Earnings were $581.78 million, an increase of 36.02%.
Analyst Forecasts
According to 9 analysts, the average rating for IDXX stock is "Buy." The 12-month stock price forecast is 580.33, which is an increase of 8.84% from the latest price.